Open AccessTHIS ARTICLE HAS BEEN RETRACTED
Hamycin treatment of candidiasis in normal and diabetic rats
Author(s) -
Dhuley Jayant N
Publication year - 1999
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.1999.tb01386.x
Subject(s) - amphotericin b , candida albicans , antibiotics , mycosis , streptozotocin , diabetes mellitus , biology , medicine , pharmacology , antifungal , endocrinology , microbiology and biotechnology , immunology
Hamycin, a heptaene antifungal antibiotic was compared with amphotericin B in the treatment of established systemic infection with Candida albicans in normal and diabetic rats. In normal rats, orally administered hamycin at 10 mg kg −1 per day for 7 days reduced Candida colony counts in the kidneys and livers as well as amphotericin B did and was nearly as effective as amphotericin B in a 21‐day treatment trial. There was no further reduction in Candida colony counts when normal rats were treated with hamycin at 25 mg kg −1 twice a day for 7 days. In streptozotocin induced diabetic rats, hamycin at 20 mg kg −1 per day for either 7 or 21 days compared favourably with amphotericin B in efficacy. Results of the present study suggest that oral hamycin may be useful in the treatment of established disseminated candidiasis in normal as well as diabetic hosts.